Edmonton's Aurora Cannabis agrees to sell to Organigram, eight years after the legalization boom
Organigram Global Inc. agreed to acquire Aurora Cannabis Inc. for approximately $561 million, outbidding a hostile offer from Curaleaf Holdings Inc. Aurora's CEO highlighted the strategic fit, combining Aurora's international medical cannabis strengths with Organigram's Canadian recreational market dominance. The deal offers Aurora shareholders $7.80 per share in cash, stock, or a mix, with cash capped at $253.6 million. Aurora's stock closed at $7.24 on the Toronto Stock Exchange.
How this was made
The 30-second read
Why it matters
The merger creates the largest Canadian cannabis operator, potentially improving economies of scale and market reach.
Market read
Deal reshapes the Canadian cannabis landscape and may trigger re‑rating of peer stocks.
What to watch
Regulatory changes in Canada and potential U.S. market expansion could alter the long‑term value of the combined entity.
Background
The transaction follows a previous hostile offer from Curaleaf that was outbid by Organigram.
Ticker impact
Aurora Cannabis announced a $561 million sale to Organigram, offering $7.80 per share in cash and/or shares.
upward pressure as market prices in the $7.80 per share offer
The cash component is capped at $253.6 M, but the premium to the last close ($7.24) suggests a near‑term rally.
Market effects
Consolidation in Canadian cannabis sector may pressure peers' valuations.
Toronto market may see heightened activity in cannabis stocks.
Creates a larger integrated player that could affect international cannabis investment flows.
Counterpoint
The premium may be insufficient given integration risks; the deal could erode Organigram's balance sheet.
Key entities
- CompanyAurora Cannabis Inc.
Canadian medical cannabis producer being acquired.
- CompanyOrganigram Global Inc.
Canadian recreational cannabis leader acquiring Aurora.
